AxoGen (AXGN) News Today

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) saw a large decline in short interest in July. As of July 31st, there was short interest totalling 1,960,000 shares, a decline of 19.7% from the July 15th total of 2,440,000 shares. Based on an average trading volume of 387,700 shares, the days-to-cover ratio is currently 5.1 days.

Assenagon Asset Management S.A. grew its stake in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 2,014.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,310,811 shares of the medical equipment provider's stock

AxoGen (NASDAQ:AXGN) Reaches New 52-Week High at $11.57

Vanguard Group Inc. trimmed its stake in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 2.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,411,403 shares of the medical equipment provider'

StockNews.com upgraded AxoGen from a "hold" rating to a "buy" rating in a research note on Friday.

Shares of AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) have been given a consensus rating of "Buy" by the four research firms that are currently covering the company, Marketbeat reports. Four research analysts have rated the stock with a buy rating. The average twelve-month target price among brok

AxoGen (NASDAQ:AXGN) will be releasing earnings before the market opens on Thursday, August 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=611667)

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 2,150,000 shares, an increase of 12.0% from the June 15th total of 1,920,000 shares. Based on an average daily volume of 320,100 shares, the short-interest ratio is presently 6.7 days.

Raymond James began coverage on shares of AxoGen in a research note on Monday. They issued an "outperform" rating and a $13.00 target price for the company.

Canaccord Genuity Group restated a "buy" rating and issued a $15.00 price objective on shares of AxoGen in a report on Thursday.

First Light Asset Management LLC cut its stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 85.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 276,489 shares of the medical equipment provider's stock after se

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 1,820,000 shares, a growth of 9.0% from the April 15th total of 1,670,000 shares. Based on an average daily volume of 370,900 shares, the days-to-cover ratio is currently 4.9 days.

StockNews.com cut AxoGen from a "buy" rating to a "hold" rating in a report on Monday.

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 1,700,000 shares, a growth of 21.4% from the February 29th total of 1,400,000 shares. Based on an average daily trading volume, of 427,600 shares, the short-interest ratio is currently 4.0 days. Currently, 4.2% of the shares of the company are sold short.

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) insider Erick Wayne Devinney sold 4,578 shares of the stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $7.68, for a total value of $35,159.04. Following the completion of the transaction, the insider now directly owns 165,661 shares in the company, valued at $1,272,276.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) Director Gregory Gene Freitag sold 25,000 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $9.00, for a total transaction of $225,000.00. Following the transaction, the director now owns 271,594 shares in the company, valued at $2,444,346. The sale was disclosed in a filing with the SEC, which is available through this link.